Dementia in Parkinson's disease

Journal of Neurology

Volumn 254, Issue SUPPL. 5, 2007, Pages 41-48

  Martí, Maria J ^a   Tolosa, Eduardo ^a,b   De La Cerda, Andres ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cholinesterase inhibitor; Cortical Lewy body; Dementia; Executive dysfunction; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MONOAMINE; NEUROLEPTIC AGENT; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; BRAIN CORTEX; CAREGIVER; CHOLINERGIC ACTIVITY; COGNITION; CONFERENCE PAPER; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; FOLLOW UP; HUMAN; LEWY BODY; MINI MENTAL STATE EXAMINATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR;

EID: 34548743540     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-5007-5     Document Type: Conference Paper

References (67)

1. Aarsland D, Andersen K, Larsen MD, Lolk A, Kragh-Sørensen P (2003) Prevalence and characteristics of dementia in Parkinson's disease: an 8-year prospective study. Arch Neurol 60:387-392
2. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P (2001) Risk of dementia in Parkinson's disease: a community-based prospective study. Neurology 56:730-736
3. Aarsland D, Ballard C, Larsen JP, McKeith I (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 16:528-536
4. Aarsland D, Cummings JL, Larsen JP (2001) Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 16:184-191
5. Aarsland D, Hutchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18:937-941
6. Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72:708-712
7. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E (1999) Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriat Psychiatry 14:866-874
8. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 20:1255-1263
9. th ed. American Psychiatric Association, Washington DC
10. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson's disease neuropathology. Later-developing dementia and loss of the levodopa response. Arch Neurol 59:102-112
11. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormaak F, Burn D, Cassidy T, Starfeldt R, Larsen J-P, Brown R, Tovee M (2002) Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59:1714-1720
12. Boeve B, Silver M, Ferman T (2003) Melatonin for treatment of REM sleep behaviour disorder in neurological disorders: results in 14 patients. Sleep Med 4:281-284
13. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer's disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745-1748
14. Bosboom JLW, Stoffers D, Wolters EC (2004) Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 111:1303-1315
15. Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
16. Braak H, Rüb U, Jansen Steur ENH, Del Tredici K, de Vos RAI (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404-1410
17. Bronnick K, Aarsland D, Larsen JP (2005) Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand 112:201-207
18. Colosimo C, Hughes AJ, Kilford L, Lees AJ (2003) Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg 74:852-856
19. Cummings JL (2005) Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 76:903-904
20. De Vos RAI, Jansen ENH, Stam FC, Ravid R, Swaab DF (1995) "Lewy body disease": clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 97:13-22
21. Emre M (2003) Dementia associated with Parkinson's disease. Lancet Neurol 2:229-237
22. Emre M (2004) Dementia in Parkinson's disease: cause and treatment. Curr Opin Neurol 17:399-404
23. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, Van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351:2509-2518
24. Fénelon G, Mahieux F, Huon R, Ziégler M (2000) Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 123:733-745
25. French Clozapine Parkinson Study Group (1999) Clozapine in druginduced psychosis in Parkinson's disease. Lancet 353:2041-2042
26. Friedman JH, Fernandez HH (2002) Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol 15:156-170
27. Gjerstad MD, Aarsland D, Larsen JP (2002) Development of daytime somnolence over time in Parkinson's disease. Neurology 58:1544-1546
28. Growdon JH, Kieburtz K, Mc Dermott MP, Panisset M, Friedman JH (1998) Levodopa improves motor function without impairing cognition in mild non demented Parkinson's disease patients. Neurology 50:1327-1331
29. Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 19:1043-1049
30. Huber SJ, Shuttleworth EC, Freidenberg DL (1989) Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases. Arch Neurol 46:1287-1291
31. Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50:140-148
32. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RHS, Spokes EGS (2000) A 10-year study of the incidence and factors predicting dementia in Parkinson's disease. Neurology 54:1596-1602
33. Hurtig HI, Trojanowski JQ,Galvin J, Ewbank D, Schmidt ML, Lee VM-Y, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alphasynuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54:1916-1921
34. Jacobs DM, Marder K, Coté LJ, Sano M, Stern Y, Mayeux R (1995) Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology 45:1691-1696
35. Janvin CC, Aarsland D, Larsen JP (2005) Cognitive predictors of dementia in Parkinson's disease: a community-based 4-year longitudinal study. J Geriatr Psychiatry Neurol 18:149-154
36. Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109:329-339
37. Kosaka K (1994) Diffuse neurofibrillary tangles with calcifications: a new presenile dementia. J Neurol Neurosurg Psychiatry 57:594-596
38. Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estévez-González A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year-follow-up study of previously untreated patients. Mov Disord 15:613-626
39. Lange KW, Paul GM, Naumann M, Gsell W (1995) Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J Neural Transm 46(Suppl):423-432
40. Levy G, Jacobs DM, Tang MX, Côté LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K (2002) Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 17:1221-1226
41. Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002) Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 51:722-729
42. Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K (2000) Motor impairment in PD: relationship to incident dementia and age. Neurology 55:539-544
43. Levy G, Tang MX, Louis ED, Côté LJ, Alfaro B, Mejia H, Stern Y, Marder K (2002) The association of incident dementia with mortality in PD. Neurology 59:1708-1713
44. Lewis SJG, Slabosz A, Robbins TW, Barker RA, Owen AM (2005) Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 43:823-832
45. Litvan I, Mohr E, Williams J, Gomez C, Chase TN (1991) Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry 54:25-29
46. Mahieux F, Fénelon G, Flahault A, Manifacier M-J, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 64:178-183
47. Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 52:695-701
48. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98:12245-12250
49. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M (2000) Alphasynuclein- immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 100:285-290
50. Mattila PM, Roytta M, Lonnberg P, Marjamäki P, Helenius H, Rinne JO (2001) Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol 102:160-166
51. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, Basile G, Di Raimondo G, La Spina P, Quattrone A (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27:153-156
52. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y (2004) Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 19:60-67
53. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17:1031-1035
54. Parkinson Study Group (1999) Lowdose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340:757-763
55. Perry EK, Curtis M, Dick DJ (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48:413-421
56. Perry RH, Tomlinson BE, Candy JM, Blessed G, Foster JF, Bloxham CA, Perry ER (1983) Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet 2:789-790
57. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T (2005) Donepezil for dementia in Parkinson's disease: a randomized, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76:934-939
58. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK (1989) Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26:47-50
59. SantaCruz K, Pahwa R, Lyions K, Troster A, Handler M, Koller W, De Carli C (1999) Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson's disease patients with and without dementia. Neurology 52(Suppl 2):A476-A477
60. Schrag A (2004) Psychiatric aspects of Parkinson's disease. An update. J Neurol 251:795-804
61. Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 43:1690-1692
62. Stern Y, Tetrud JW, Martin WRW, Kutner SJ, Langston JW (1990) Cognitive change following MPTP exposure. Neurology 40:261-264
63. Tandberg E, Larsen JP, Aarsland D, Cummings JL (1996) The occurrence of depression in Parkinson's disease: a community-based study. Arch Neurol 53:175-179
64. Tandberg E, Larsen JP, Karlsen KH (1999) Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 14:922-927
65. Valldeoriola F, Nobbe FA, Tolosa E (1997) Treatment of behavioural disturbances in Parkinson's disease. J Neural Transm Suppl 51:157-204
66. Whitehouse PJ, Hedreen JC, White CL, Price DL (1983) Basal forebrain neurons in the dementia of Parkinson's disease. Ann Neurol 13:243-248
67. Zgaljardic DJ, Foldi NS, Borod JC (2004) Cognitive and behavioural dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J Neural Transm 111:1287-1301